Concord Biotech Ltd.
Fundamentals
- Market cap
- ₹10,997 cr
- P/E
- 35.19×
- ROE
- 20.50%
- Debt / equity
- 0.00
- Div yield
- 1.02%
- 52-week range
- 987.00 — 2150.40
The timeline — 3 notes on Concord Biotech Ltd.
May 2026
- 29 May 26 · 8:39 PM IST Brief Brief · Earnings · Mid cap
Concord Biotech profit falls 30% on a 12% revenue slide
The Ahmedabad drug maker's annual results confirm a tough fiscal year, with net profit at ₹259.23 cr and revenue at ₹1,054.89 cr. The board still declared a dividend.
- 29 May 26 · 8:17 PM IST Brief Brief · Earnings · Mid cap
Concord Biotech profit falls 30% as revenue contracts 11%
FY26 net profit dropped to ₹259.23 crore from ₹371.64 crore, with total income shrinking to ₹1,107.25 crore.
- 29 May 26 · 7:53 PM IST Brief Brief · Earnings · Mid cap
Concord Biotech profit drops 30% as revenue contracts for the year
The Ahmedabad-based drugmaker's net profit fell to ₹259 crore as revenue shrank 12%, overshadowing a ₹7.55 dividend.